These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
420 related articles for article (PubMed ID: 32267005)
1. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis. Krysko KM; Graves JS; Rensel M; Weinstock-Guttman B; Rutatangwa A; Aaen G; Belman A; Benson L; Chitnis T; Gorman M; Goyal MS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rodriguez M; Rose J; Schreiner T; Tillema JM; Waltz M; Casper TC; Waubant E; Ann Neurol; 2020 Jul; 88(1):42-55. PubMed ID: 32267005 [TBL] [Abstract][Full Text] [Related]
2. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year. Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986 [TBL] [Abstract][Full Text] [Related]
3. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Krysko KM; Graves J; Rensel M; Weinstock-Guttman B; Aaen G; Benson L; Chitnis T; Gorman M; Goyal M; Krupp L; Lotze T; Mar S; Rodriguez M; Rose J; Waltz M; Charles Casper T; Waubant E; Neurology; 2018 Nov; 91(19):e1778-e1787. PubMed ID: 30333163 [TBL] [Abstract][Full Text] [Related]
4. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858 [TBL] [Abstract][Full Text] [Related]
5. Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Abdel-Mannan OA; Manchoon C; Rossor T; Southin JC; Tur C; Brownlee W; Byrne S; Chitre M; Coles A; Forsyth R; Kneen R; Mankad K; Ram D; West S; Wright S; Wassmer E; Lim M; Ciccarelli O; Hemingway C; Hacohen Y; Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 34021056 [TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484 [TBL] [Abstract][Full Text] [Related]
7. Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments. Malani Shukla N; Casper TC; Ness J; Wheeler Y; Chitnis T; Lotze T; Gorman M; Benson L; Weinstock-Guttmann B; Aaen G; Rodriguez M; Tillema JM; Krupp L; Schreiner T; Mar S; Goyal M; Rensel M; Abrams A; Rose J; Waltz M; Liu T; Manlius C; Waubant E; Pediatr Neurol; 2023 Aug; 145():125-131. PubMed ID: 37348193 [TBL] [Abstract][Full Text] [Related]
8. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data. Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609 [TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221 [TBL] [Abstract][Full Text] [Related]
10. Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019. Duchesneau ED; Kinlaw AC; Jonsson Funk M; Pate V; Lund JL Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):481-487. PubMed ID: 35088492 [TBL] [Abstract][Full Text] [Related]
11. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T; JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031 [TBL] [Abstract][Full Text] [Related]
12. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis. Neuberger EE; Abbass IM; Jones E; Engmann NJ Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713 [TBL] [Abstract][Full Text] [Related]
13. Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study. Saponaro AC; Tully T; Maillart E; Maurey H; Deiva K; Eur J Paediatr Neurol; 2023 Jul; 45():22-28. PubMed ID: 37245449 [TBL] [Abstract][Full Text] [Related]
14. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Eagle T; Stuart F; Chua AS; LaRussa A; Leclaire K; Cook SL; Chitnis T; Weiner HL; Glanz BI; Healy BC Mult Scler Relat Disord; 2017 Nov; 18():196-201. PubMed ID: 29141809 [TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related]
17. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581 [TBL] [Abstract][Full Text] [Related]
18. Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis. Dolladille C; Chrétien B; Peyro-Saint-Paul L; Alexandre J; Dejardin O; Fedrizzi S; Defer G Neurotherapeutics; 2021 Jul; 18(3):1657-1664. PubMed ID: 34231126 [TBL] [Abstract][Full Text] [Related]
19. Nocebo in multiple sclerosis trials: A meta-analysis on oral and newer injectable disease-modifying treatments. Gklinos P; Papadopoulos D; Mitsikostas DD Mult Scler Relat Disord; 2019 Nov; 36():101389. PubMed ID: 31525626 [TBL] [Abstract][Full Text] [Related]
20. Prescription trends of disease-modifying treatments for multiple sclerosis in Iran over the past 30 years. Ghadiri F; Sahraian MA; Baghbanian SM; Ashtari F; Razazian N; Majdinasab N; Poursadeghfard M; Hatamian H; Harirchian MH; Beladimoghadam N; Azimi A; Sharifipour E; Hosseini S; Bayati A; Kamali H; Hosseni Nejad Mir N; Faraji F; Mozhdehipanah H; Modara F; Navardi S; Heidari H; Ayoubi S; Naser Moghadasi A; Eskandarieh S Mult Scler Relat Disord; 2022 May; 61():103777. PubMed ID: 35390594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]